Indeed, LIMK1 and LIMK2 have been shown to be upregulated in breast cancer [58], gastric cancer [59], prostate cancer [92,93], and malignant melanoma cells [94], and they seem to be involved in multiple non-canonical signalling pathways that, when dysregulated, actively participate in tumorigenesis. The gene discussed is LIMK1; the disease is prostate carcinoma.